Various embodiments relate to a compound of the formula (I) and (II), wherein X, X.sup.1, X.sup.2, X.sup.3, and R.sup.1-R.sup.4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Various embodiments relate to a compound of the formula (I) and (II), wherein X, X.sup.1, X.sup.2, X.sup.3, and R.sup.1-R.sup.4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

##STR00001##

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

##STR00001##

The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) where: (i) R.sup.1 is chosen from the group constituted of —CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, or cyclohexyl, (ii) X represents —CH.sub.2—CH.sub.2—, or —CH═CH—, (iii) R.sup.2 is chosen from

##STR00001##

or an OH group, (iv) R.sup.3 is OH or NOH, (v) represents a single bond when R.sup.3 is OH, or a double bond when R.sup.3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.

The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) where: (i) R.sup.1 is chosen from the group constituted of —CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, or cyclohexyl, (ii) X represents —CH.sub.2—CH.sub.2—, or —CH═CH—, (iii) R.sup.2 is chosen from

##STR00001##

or an OH group, (iv) R.sup.3 is OH or NOH, (v) represents a single bond when R.sup.3 is OH, or a double bond when R.sup.3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.

Various embodiments relate to a compound of the formula (I) and (II), wherein X, X.sup.1, X.sup.2, X.sup.3, and R.sup.1-R.sup.4 am defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Various embodiments relate to a compound of the formula (I) and (II), wherein X, X.sup.1, X.sup.2, X.sup.3, and R.sup.1-R.sup.4 am defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Methods of making low odor choline salts of an organic compound, for example, choline ellagate compound(s), and uses and formulations thereof.

Methods of making low odor choline salts of an organic compound, for example, choline ellagate compound(s), and uses and formulations thereof.